Emmaus Medical, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.emmausmedical.com
L-glutamine Treatment in Patients With Diverticulosis
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Emmaus Medical, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05106101
- Locations
- 🇺🇸
The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸Ventura Clinical Trials, Ventura, California, United States
Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Emmaus Medical, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT04684381
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Emmaus Medical, Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT01179217
- Locations
- 🇺🇸
Howard University Hospital & Howard University, Washington, District of Columbia, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Interfaith Medical Center, Brooklyn, New York, United States
L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Emmaus Medical, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT00125788
- Locations
- 🇺🇸
Kaiser Permanente, Bellflower, California, United States
🇺🇸Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Jacobi Medical Center, Bronx, New York, United States
© Copyright 2024. All Rights Reserved by MedPath